Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE

PFIZER INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 35.48, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 35.28 support.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • With a P/E ratio at 13.34 for the current year and 15.25 for next year, earnings multiples are highly attractive compared with competitors.
  • This company will be of major interest to investors in search of a high dividend stock.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 35.48 USD
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 5.1 times its current sales, is high.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • Analysts covering the stock have recently lowered their earnings forecast.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
PFIZER INC.-0.30%203 993
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
ABBVIE INC.3.15%195 120
ELI LILLY AND COMPANY12.99%172 949
NOVO NORDISK A/S3.72%166 434
BRISTOL-MYERS SQUIBB COMPAN..7.27%150 364
AMGEN INC.6.77%142 917
ASTRAZENECA PLC3.66%135 464
SANOFI3.60%123 845
GLAXOSMITHKLINE PLC5.34%95 888
CHUGAI PHARMACEUTICAL CO., ..7.11%93 341
JIANGSU HENGRUI MEDICINE CO..-1.46%89 987
DAIICHI SANKYO COMPANY, LIM..3.93%68 450
More Results
Financials (USD)
Sales 2020 48 571 M - -
Net income 2020 17 066 M - -
Net Debt 2020 43 571 M - -
P/E ratio 2020 13,3x
Yield 2020 3,92%
Capitalization 204 B 204 B -
EV / Sales 2020 5,10x
EV / Sales 2021 4,44x
Nbr of Employees 88 300
Free-Float 59,1%
Upcoming event on PFIZER INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes